Cancer survival in England remains lower than countries with similar healthcare systems, according to a new Cancer Research UK funded study published in the British Journal of Cancer today.
Cancer survival in England has steadily improved but the gap in survival remains.
The research, from the London School of Hygiene & Tropical Medicine, compared survival for colon, breast, lung, ovarian, rectal and stomach cancers in England, Australia, Canada, Denmark, Norway and Sweden between 1995 and 2009, and survival trends in England up to 2012*. It included more than 1.9 million cancer patients in England and another 1.9 million cancer patients from the other five countries.
Of all six countries cancer survival was lowest in England, while Australia and Sweden had the highest cancer survival overall**.
Compared with the better performing countries - Australia, Canada, Norway and Sweden -five-year survival was five to twelve per cent lower in England across all the cancer types measured***.
Despite this England's survival continues to improve, in some cases faster than elsewhere. Five-year survival from breast cancer improved more in England than in the four leading countries. And survival for all cancers except ovarian improved faster in England than Australia****.
The faster improvements in survival could be down to the fact that there was more to be done to improve survival in England - diagnosing patients earlier and making sure more people can be given the best treatments - than in the countries that already had higher cancer survival.
Recent years have seen important increases in survival from some cancers. For example, while there was little or no change in five-year survival from lung cancer up to the mid-2000s in England, there has been steady improvement since then, up to one per cent per year during 2010-2012.
Lead author Dr Sarah Walters, from the Cancer Survival Group at the London School of Hygiene & Tropical Medicine, said: "The way England's cancer survival has improved shows promise, but it's vital that more is done to ensure England closes this gap and that more people survive cancer for longer. The rapid improvements we've seen over the past 20 years have been driven by better investment, setting and measuring targets within the NHS, and developing new ways to diagnose and treat cancer. If we are to improve further it is vital we continue to work on these areas."
These findings are published after the Independent Cancer Taskforce announced plans to save many thousands more lives and transform patient experience and quality of life. This will be achieved by diagnosing patients earlier, making sure patients are given the best treatment, preventing more cases of cancer, transforming support for people living with and beyond cancer and providing a better experience for patients.
Sara Hiom, Cancer Research UK's director of early diagnosis, said: "Not only is England struggling to excel on an international level - there's also too much variation across the country in the speed with which patients are diagnosed and whether they can get the treatments they need.
"The good news is that it seems previous improvements - in cancer awareness, services and treatments - mean we're now seeing some improvements in survival. But we must do more of what we're learning works. This means providing world-class funding for our cancer services and these services working together more effectively, if we want to achieve world class cancer survival."
For media enquiries contact the Cancer Research UK press office on 020 3469 8300 or, out of hours, on 07050 264 059.
Walters et al. Is England closing the international gap in cancer survival? British Journal of Cancer. DOI: 10.1038/bjc.2015.265
* The report analysed data from Australia, Canada, Denmark, Norway and Sweden between 1995 and 2009 and data from England between 1995 and 2012.
** Cancer survival in Denmark was generally better than in England in 2005-2009, except for one-year survival of stomach cancer and five-year survival of stomach and breast cancer where England performed similarly.
*** Patients diagnosed between 2005 and 2009.
**** Comparing patients diagnosed during 2005-2009 with those diagnosed in 1995-1999.